Oncology

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about the potential of AI to affect development and use of cell and gene therapy products.

Take a look what stood out as pillars of progress and success from all of CGTLive's most popular oncology stories in 2025.

In this bonus episode of ImmunoLogic, the hosts discussed highlights from 2025, including some covered in previous episodes of the series.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on cost reduction for cell and gene therapy products.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on the field's future.

Recapping some the FDA approvals and regulatory updates in cell and gene therapy that made waves in 2025.

In this bonus episode of ImmunoLogic, the hosts discussed immunotherapy highlights from ASH's annual meeting.

The trial is open to patients with a wide array of solid tumor indications.

Review top news and interview highlights from the week ending December 19, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on the importance of big wins for those in research.

Review top news and interview highlights from the week ending December 12, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The Fondazione Telethon agent, etuvetidigene autotemcel, significantly reduced severe infections and bleeding events in clinical studies.

Deevyashali Parekh, MBBS, an internal medicine resident at SUNY Upstate Medical University Hospital, discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

ImmunoLogic cohost Janna Minehart, MD, discussed a few exciting immunotherapy sessions she attended at ASH's Annual Meeting.

The internal medicine resident at SUNY Upstate Medical University Hospital discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

The clinical fellow in hematology/oncology at the University of Pennsylvania discussed several sessions she's excited about at the ASH Annual Meeting.

AZD0120, a dual-targeted CAR T-cell therapy, shows high efficacy in treating relapsed multiple myeloma, achieving a 96% response rate.

Review top news and interview highlights from the week ending December 5, 2025.

The agency's decision was based on results from an r/r MZL cohort in the phase 2 TRANSCEND FL clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed lessons that should guide the next generation of developers and regulators entering the field.

In episode 7 of ImmunoLogic, Anusha Kalbasi, MD, discussed his research on the use of IL-9 to enhance CAR-T efficacy.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.